| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 19.238 | 21.954 | 22.624 | 22.389 | 19.440 | 20.940 | 23.111 | 19.027 | 23.832 |
| Total Income - EUR | - | 19.238 | 21.954 | 22.624 | 22.390 | 19.440 | 20.940 | 23.111 | 19.027 | 23.832 |
| Total Expenses - EUR | - | 1.897 | 10.019 | 6.861 | 4.718 | 4.986 | 6.574 | 10.841 | 11.672 | 14.609 |
| Gross Profit/Loss - EUR | - | 17.341 | 11.935 | 15.763 | 17.672 | 14.453 | 14.367 | 12.271 | 7.355 | 9.222 |
| Net Profit/Loss - EUR | - | 16.764 | 11.277 | 15.084 | 17.000 | 13.870 | 13.738 | 11.577 | 6.179 | 7.776 |
| Employees | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Neurosave S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | 17.037 | 12.690 | 15.364 | 17.224 | 14.191 | 13.945 | 11.818 | 17.071 | 8.176 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 144 | 77 | 680 | 889 | 1.423 | 1.514 | 1.504 | 6.851 |
| Cash | - | 17.037 | 12.545 | 15.287 | 16.544 | 13.302 | 12.522 | 10.304 | 15.567 | 1.325 |
| Shareholders Funds | - | 16.808 | 11.329 | 15.135 | 17.051 | 13.919 | 13.787 | 11.626 | 16.335 | 7.825 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 229 | 1.360 | 229 | 173 | 271 | 158 | 193 | 736 | 352 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neurosave S.r.l.